KR102613874B1 - 1가 항-프로페르딘 항체 및 항체 단편 - Google Patents

1가 항-프로페르딘 항체 및 항체 단편 Download PDF

Info

Publication number
KR102613874B1
KR102613874B1 KR1020197021910A KR20197021910A KR102613874B1 KR 102613874 B1 KR102613874 B1 KR 102613874B1 KR 1020197021910 A KR1020197021910 A KR 1020197021910A KR 20197021910 A KR20197021910 A KR 20197021910A KR 102613874 B1 KR102613874 B1 KR 102613874B1
Authority
KR
South Korea
Prior art keywords
gly
ser
ala
val
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197021910A
Other languages
English (en)
Korean (ko)
Other versions
KR20190111946A (ko
Inventor
더글라스 엘. 쉐리단
폴 피. 탐부리니
타네이샤 앤-타나라 맥
월터 씨. 뵈그틀리
Original Assignee
알렉시온 파마슈티칼스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알렉시온 파마슈티칼스, 인코포레이티드 filed Critical 알렉시온 파마슈티칼스, 인코포레이티드
Priority to KR1020237042534A priority Critical patent/KR20230173731A/ko
Publication of KR20190111946A publication Critical patent/KR20190111946A/ko
Application granted granted Critical
Publication of KR102613874B1 publication Critical patent/KR102613874B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020197021910A 2017-01-30 2018-01-30 1가 항-프로페르딘 항체 및 항체 단편 Active KR102613874B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237042534A KR20230173731A (ko) 2017-01-30 2018-01-30 1가 항-프로페르딘 항체 및 항체 단편

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762452187P 2017-01-30 2017-01-30
US62/452,187 2017-01-30
PCT/US2018/015985 WO2018140956A1 (en) 2017-01-30 2018-01-30 Monovalent anti-properdin antibodies and antibody fragments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237042534A Division KR20230173731A (ko) 2017-01-30 2018-01-30 1가 항-프로페르딘 항체 및 항체 단편

Publications (2)

Publication Number Publication Date
KR20190111946A KR20190111946A (ko) 2019-10-02
KR102613874B1 true KR102613874B1 (ko) 2023-12-15

Family

ID=62978808

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197021910A Active KR102613874B1 (ko) 2017-01-30 2018-01-30 1가 항-프로페르딘 항체 및 항체 단편
KR1020237042534A Ceased KR20230173731A (ko) 2017-01-30 2018-01-30 1가 항-프로페르딘 항체 및 항체 단편

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237042534A Ceased KR20230173731A (ko) 2017-01-30 2018-01-30 1가 항-프로페르딘 항체 및 항체 단편

Country Status (12)

Country Link
US (3) US11198725B2 (https=)
EP (1) EP3573661A4 (https=)
JP (3) JP7101684B2 (https=)
KR (2) KR102613874B1 (https=)
CN (2) CN110831626B (https=)
AU (2) AU2018212012B2 (https=)
BR (1) BR112019014652A2 (https=)
CA (1) CA3049806A1 (https=)
CO (1) CO2019007686A2 (https=)
IL (2) IL267898B2 (https=)
MX (3) MX2019008827A (https=)
WO (1) WO2018140956A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019008827A (es) * 2017-01-30 2019-09-26 Alexion Pharma Inc Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
KR102806328B1 (ko) * 2017-07-11 2025-05-14 알렉시온 파마슈티칼스, 인코포레이티드 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질
JP7222075B2 (ja) * 2018-09-13 2023-02-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃ３糸球体症のモデルとしての補体因子ｈ遺伝子ノックアウトラット
US12570732B2 (en) 2020-01-08 2026-03-10 Zydus Lifesciences Limited Anti-properdin antibodies and preparation thereof
CN116437913A (zh) 2020-09-23 2023-07-14 艾其林医药公司 用于治疗补体介导的病症的药物化合物
CN118436786A (zh) * 2020-10-30 2024-08-06 广州市妇女儿童医疗中心 诊治胆道闭锁的方法
WO2023023227A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
US11981727B2 (en) 2021-08-31 2024-05-14 Novelmed Therapeutics, Inc Monospecific and bispecific antibodies and antigen binding fragments thereof
WO2024108529A1 (en) * 2022-11-25 2024-05-30 Linno Pharmaceuticals Inc. Properdin binding protein and use thereof
CA3264087A1 (en) * 2022-08-05 2024-02-08 Alexion Pharmaceuticals, Inc. Pharmaceutical compositions based on fusion proteins and their methods of use
CN120018862A (zh) * 2022-08-31 2025-05-16 阿雷克森制药公司 用于治疗镰状细胞病的融合多肽的剂量和施用
KR20250112858A (ko) 2022-11-25 2025-07-24 리노 파마슈티컬스 아이엔씨. 프로퍼딘 결합 단백질 및 이의 용도
CN120399074B (zh) * 2023-06-02 2025-12-30 安徽金百奥生物科技有限公司 一种与人dr3胞外域高亲和力的纳米抗体

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
BRPI0606934A2 (pt) 2005-01-25 2017-07-11 Cell Therapeutics Inc Conjugado de proteína biologicamente ativa, composição, molécula de dna quimérica, vetor, célula, e, métodos para preparar conjugado de proteína biologicamente ativa, e para determinar se um dado conjugado de proteína exibe uma meia-vida de plasma modificada comparada com a meia-vida intrínseca do polipeptídeo biologicamente ativo não conjungado
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
SG10201804008UA (en) * 2005-11-04 2018-06-28 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
DK2262831T3 (en) * 2008-03-03 2015-04-27 Novelmed Therapeutics Inc ANTI-Properdin ANTIBODIES
CA2766565A1 (en) 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
US20110172398A1 (en) 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
CA2811221C (en) * 2010-03-10 2018-01-09 Novelmed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
PT2621515T (pt) 2010-09-28 2017-07-12 Aegerion Pharmaceuticals Inc Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
AU2011328246B2 (en) 2010-11-08 2016-06-30 Ablynx N.V. CXCR2 binding polypeptides
KR20140064768A (ko) 2011-07-01 2014-05-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항-프로퍼딘 항체 및 그의 용도
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
ES2728278T3 (es) * 2011-12-21 2019-10-23 Novartis Ag Composiciones que comprenden anticuerpos dirigidos al factor P y C5
WO2013102123A2 (en) 2011-12-28 2013-07-04 Novelmed Therapeutics, Inc. Aglycosylated human antibody and fusion protein and uses thereof
CA2887050A1 (en) 2012-10-04 2014-04-10 Novelmed Therapeutics, Inc. Alternative pathway specific antibodies for treating hemolytic diseases
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
MX2019008827A (es) * 2017-01-30 2019-09-26 Alexion Pharma Inc Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
CN110003335B (zh) * 2019-04-12 2023-07-04 深圳普瑞金生物药业股份有限公司 Cd47单域抗体、核酸及试剂盒

Also Published As

Publication number Publication date
AU2025200709A1 (en) 2025-02-20
RU2019124873A (ru) 2021-03-01
MX2019008827A (es) 2019-09-26
RU2019124873A3 (https=) 2021-03-01
JP2022153405A (ja) 2022-10-12
US20190352381A1 (en) 2019-11-21
MX2023007840A (es) 2023-07-07
MX2023004333A (es) 2023-05-04
JP7101684B2 (ja) 2022-07-15
EP3573661A1 (en) 2019-12-04
AU2018212012A1 (en) 2019-07-25
US11198725B2 (en) 2021-12-14
IL267898A (en) 2019-09-26
JP2024116321A (ja) 2024-08-27
US12497445B2 (en) 2025-12-16
KR20190111946A (ko) 2019-10-02
EP3573661A4 (en) 2020-08-12
BR112019014652A2 (pt) 2020-08-18
US20220162292A1 (en) 2022-05-26
CA3049806A1 (en) 2018-08-02
IL309890A (en) 2024-03-01
CO2019007686A2 (es) 2019-07-31
KR20230173731A (ko) 2023-12-27
US20260070963A1 (en) 2026-03-12
WO2018140956A1 (en) 2018-08-02
IL267898B1 (en) 2024-02-01
CN110831626B (zh) 2024-04-19
AU2018212012B2 (en) 2025-02-13
JP2020507561A (ja) 2020-03-12
CN118184777A (zh) 2024-06-14
IL267898B2 (en) 2024-06-01
CN110831626A (zh) 2020-02-21

Similar Documents

Publication Publication Date Title
KR102613874B1 (ko) 1가 항-프로페르딘 항체 및 항체 단편
US20250163138A1 (en) Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
US20240024520A1 (en) Autonomous knob domain peptides
RU2790103C2 (ru) Моновалентные антитела к пропердину и фрагменты антител
HK40112563A (zh) 单价抗备解素抗体及抗体片段
HK40024594A (en) Monovalent anti-properdin antibodies and antibody fragments
HK40024594B (zh) 单价抗备解素抗体及抗体片段
WO2024108529A1 (en) Properdin binding protein and use thereof
RU2794359C2 (ru) Полипептиды, которые связываются с компонентом комплемента c5 или сывороточным альбумином, и их белки слияния
EP4396226A2 (en) Monospecific and bispecific antibodies and antigen binding fragments thereof
HK40027205A (en) Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190725

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210119

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230220

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230909

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231211

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231212

End annual number: 3

Start annual number: 1

PG1601 Publication of registration